Ovid Therapeutics/$OVID
1D1W1MYTD1Y5YMAX
Capital at risk
About Ovid Therapeutics
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
- Ticker
- $OVID
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 23
- Headquarters
- New York, United States
- Website
- www.ovidrx.com
OVID Metrics
BasicAdvanced
$514M
-
-$0.28
0.23
-
Price and volume
Market cap
$514M
Beta
0.23
52-week high
$3.11
52-week low
$1.12
Average daily volume
1.5M
Financial strength
Current ratio
12.386
Quick ratio
11.745
Long term debt to equity
5.351
Total debt to equity
6.058
Profitability
EBITDA (TTM)
-57.974
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,178.84%
Operating margin (TTM)
-3,667.59%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-23.46%
Return on equity (TTM)
-25.96%
Valuation
Price to revenue (TTM)
201.919
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-5.836
Free cash flow yield (TTM)
-17.14%
Free cash flow per share (TTM)
-0.451
Growth
Revenue change (TTM)
-76.20%
Earnings per share change (TTM)
-46.69%
3-year revenue growth (CAGR)
99.83%
3-year earnings per share growth (CAGR)
-26.00%
What the Analysts think about OVID
Analyst ratings (Buy, Hold, Sell) for Ovid Therapeutics stock.
Analyst projections of the future price of Ovid Therapeutics stock.
Bulls say / Bears say
Ovid ended Q2 with $169.8 million in cash, cash equivalents and marketable securities, providing a financial runway into 2029 that supports ongoing clinical programs. (GlobeNewswire)
The company’s first-ever oral KCC2 activator, OV4071, advanced through a Phase 1 study in healthy volunteers, with a ketamine challenge study planned for late 2026 to de-risk and inform Phase 2 schizophrenia trials. (GlobeNewswire)
Through a transaction with Perceptive Advisors and Takeda, Ovid secured equity in a new privately held company for soticlestat with the potential to receive up to $294.5 million in clinical, regulatory and commercial milestone payments plus low-to-mid single-digit royalties upon commercialization. (GlobeNewswire)
License and other revenue fell 88% year-over-year to $0.7 million in Q2 2026 from $6.3 million in Q2 2025, reflecting a steep decline in near-term revenue sources. (GlobeNewswire)
Ovid’s net loss widened to $15.0 million (−$0.08 per share) in Q2 2026 from $4.7 million (−$0.06 per share) a year earlier, intensifying pressure on the company’s cash reserves. (GlobeNewswire)
Research and development expenses increased by 54% year-over-year to $10.0 million in Q2 2026, driving a higher cash burn amid preclinical and clinical expansion. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
OVID Financial Performance
Revenues and expenses
OVID Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing OVID
Fund name | Fund size | $OVID weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.